Robert Valencia

Robert Valencia

Auto-generated profile, based on publicly available information

Robert Valencia

Department of Pharmacology, Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NMNatsumi Miyazaki
Natsumi Miyazaki
RSReika Shiratori
Reika Shiratori
TOTaichi Oshima
Taichi Oshima
ZZZhiheng Zhang
Zhiheng Zhang
RVRobert Valencia
Robert Valencia
SAShigeki Aoki
Shigeki Aoki

28 June 2024 in The FASEB Journal
Verified
Journal Article
Open access
RVRobert Valencia
Robert Valencia
JKJoshua Walter Kranrod
Joshua Walter Kranrod
LFLiye Fang
Liye Fang
ASAmro M. Soliman
Amro M. Soliman
BABrandon Azer
Brandon Azer
JSJohn M Seubert
John M Seubert
12,13‐dihydroxy‐9z‐octadecenoic acid (12,13‐DiHOME) is a linoleic acid diol derived from cytochrome P‐450 (CYP) epoxygenase and epoxide hydrolase (EH) metabolism. 12,13‐DiHOME is associated with inflammation and mitochondrial damage in the innate immune response, but how 12,13‐DiHOME contributes to these effects is unclear. We hypothesized that 12,13‐DiHOME enhances macrophage inflammation through effects on NOD‐like receptor protein 3 (NLRP3) inflammasome activation. To test this hypothesis, we utilized human monocytic THP1 cells differentiated into macrophage‐like cells with phorbol myristate acetate (PMA). 12,13‐DiHOME present during lipopolysaccharide (LPS)‐priming of THP1 macrophages exacerbated nigericin‐induced NLRP3 inflammasome activation. Using high‐resolution respirometry, we observed that priming with LPS+12,13‐DiHOME altered mitochondrial respiratory function. Mitophagy, measured using mito‐Keima, was also modulated by 12,13‐DiHOME present during priming. These mitochondrial effects were associated with increased sensitivity to nigericin‐induced mitochondrial depolarization and reactive oxygen species production in LPS+12,13‐DiHOME‐primed macrophages. Nigericin‐induced mitochondrial damage and NLRP3 inflammasome activation in LPS+12,13‐DiHOME‐primed macrophages were ablated by the mitochondrial calcium uniporter (MCU) inhibitor, Ru265. 12,13‐DiHOME present during LPS‐priming also enhanced nigericin‐induced NLRP3 inflammasome activation in primary murine bone marrow‐derived macrophages. In summary, these data demonstrate a pro‐inflammatory role for 12,13‐DiHOME by enhancing NLRP3 inflammasome activation in macrophages.

1 October 2022 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
DSDeanna Sosnowski
Deanna Sosnowski
KJKristi Lockhart Jamieson
Kristi Lockhart Jamieson
AGArtiom Gruzdev
Artiom Gruzdev
YLYingxi Li
Yingxi Li
RVRobert Valencia
Robert Valencia
JSJohn M Seubert
John M Seubert
The cardioprotective effects of genetic disruption and pharmacological inhibition of sEH have been demonstrated in a variety of cardiac disease models, including acute LPS inflammatory injury. For the first time, it has been demonstrated that sEH genetic disruption limited to the cardiomyocyte profoundly preserves cardiac function and limits local and systemic inflammation following acute LPS exposure. Hence, cardiomyocytes serve a critical role in the innate immune response that can be modulated to protect the heart.

20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
PZPavel Zhabyeyev
Pavel Zhabyeyev
BMBrent McLean
Brent McLean
WBWesam Bassiouni
Wesam Bassiouni
RVRobert Valencia
Robert Valencia
MPManish Paul
Manish Paul
GOGavin Oudit
Gavin Oudit
Background: Identifying new therapeutic targets for preventing the myocardial ischemia–reperfusion injury would have profound implications in cardiovascular medicine. Myocardial ischemia–reperfusion injury remains a major clinical burden in patients with coronary artery disease. Methods and Results: We studied several key mechanistic pathways known to mediate cardioprotection in myocardial ischemia–reperfusion in 2 independent genetic models with reduced cardiac phosphoinositide 3‐kinase‐α (PI3Kα) activity. P3Kα‐deficient genetic models (PI3KαDN and PI3Kα‐Mer‐Cre‐Mer) showed profound resistance to myocardial ischemia–reperfusion injury. In an ex vivo reperfusion protocol, PI3Kα‐deficient hearts had an 80% recovery of function compared with ≈10% recovery in the wild‐type. Using an in vivo reperfusion protocol, PI3Kα‐deficient hearts showed a 40% reduction in infarct size compared with wild‐type hearts. Lack of PI3Kα increased late Na + current, generating an influx of Na + , facilitating the lowering of mitochondrial Ca 2+ , thereby maintaining mitochondrial membrane potential and oxidative phosphorylation. Consistent with these functional differences, mitochondrial structure in PI3Kα‐deficient hearts was preserved following ischemia–reperfusion injury. Computer modeling predicted that PIP3, the product of PI3Kα action, can interact with the murine and human Na V 1.5 channels binding to the hydrophobic pocket below the selectivity filter and occluding the channel. Conclusions: Loss of PI3Kα protects from global ischemic–reperfusion injury linked to improved mitochondrial structure and function associated with increased late Na + current. Our results strongly support enhancement of mitochondrial function as a therapeutic strategy to minimize ischemia–reperfusion injury.